{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:28:50Z","timestamp":1778030930894,"version":"3.51.4"},"reference-count":59,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":294,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J of Neuroscience"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Slowing or halting the progressive dopaminergic (DA) degeneration in Parkinson's disease (PD) would delay the onset and development of motor symptoms, prolong the efficacy of pharmacotherapies and decrease drug\u2010induced side\u2010effects. We tested the potential of two orally administered novel immunophilin ligands to protect against DA degeneration in two animal models of PD. First, in an MPTP (<jats:italic>N<\/jats:italic>\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine) mouse model, we compared an immunophilin ligand (V\u201010,367) documented to bind the immunophilin FKBP12 with V\u201013,661, which does not bind FKBP12. Both molecules could prevent the loss of striatal DA innervation in a dose\u2010dependent fashion during 10\u2003days of oral administration. Second, to determine whether an immunophilin ligand can protect against progressive and slow DA degeneration typical of PD, an intrastriatal 6\u2010hydroxydopamine\u2010infusion rat model was utilized. Oral treatment with the FKBP12\u2010binding immunophilin ligand began on the day of lesion and continued for 21\u2003days. At this time point, <jats:italic>post mortem<\/jats:italic> analyses revealed that the treatment had prevented the progressive loss of DA innervation within the striatum and loss of DA neurons within the substantia nigra, related to functional outcome as measured by rotational behaviour. Notably, DA fibres extending into the area of striatal DA denervation were observed only in rats treated with the immunophilin ligand, indicating neuroprotection or sprouting of spared DA fibres. This is the first demonstration that immunophilin ligands can prevent a slow and progressive DA axonal degeneration and neuronal death <jats:italic>in vivo<\/jats:italic>. The effects of orally administered structurally related immunophilin ligands in acute and progressive models of DA degeneration are consistent with the idea that these compounds may have therapeutic value in PD.<\/jats:p>","DOI":"10.1046\/j.0953-816x.2001.01473.x","type":"journal-article","created":{"date-parts":[[2003,3,6]],"date-time":"2003-03-06T14:38:36Z","timestamp":1046961516000},"page":"1085-1092","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease"],"prefix":"10.1111","volume":"13","author":[{"given":"Lauren C.","family":"Costantini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Pravin Chaturvedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Isacson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0730070.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.63031021.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1523\/JNEUROSCI.16-17-05437.1996","article-title":"Systemic administration of nerve growth factor conjugate reverses age\u2010related cognitive dysfunction and prevents cholinergic neuron atrophy","volume":"16","author":"Backman C.","year":"1996","journal-title":"J. Neurosci."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520090222"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1996.84.2.0203"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1997.0151"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.903550402"},{"key":"e_1_2_6_9_1","first-page":"355","article-title":"Parkinson's disease, motoneuron disease and Alzheimer's disease: origins and interrelationship","volume":"53","author":"Calne D.","year":"1990","journal-title":"Adv. Neurol."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5_Suppl_5.S17"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1998.0185"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7417"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90312-B"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.21.9808"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0397-350"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1038\/399a032","article-title":"Prospects for new restorative and neuroprotective treatments in Parkinson's disease","volume":"399","author":"Dunnett S.","year":"1999","journal-title":"Nature"},{"key":"e_1_2_6_17_1","first-page":"29","article-title":"Intracerebral grafting of neuronal cell suspensions. IV. Behavioral recovery in rats with unilateral 6\u2010OHDA lesions in different brain sites","volume":"522","author":"Dunnett S.","year":"1983","journal-title":"Acta Physiol. Scand."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(87)90269-1"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(95)00029-1"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.11.5104"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0963-6897(95)02030-6"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.15-11-07509.1995"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6630"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6684"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00221-8"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)01366-P"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440723"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130303"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490420516"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(95)00571-4"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520420033021"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00131a002"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1997.86.6.0931"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1042-3680(18)30268-7"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19971124)388:3<484::AID-CNE10>3.0.CO;2-M"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.8.3191"},{"key":"e_1_2_6_39_1","first-page":"89","article-title":"Parkinsons disease: drug therapy","volume":"6","author":"Oertel W.","year":"1997","journal-title":"Baillieres Clin. Neurol."},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440725"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.22.1.123"},{"key":"e_1_2_6_42_1","first-page":"42","article-title":"Clinical and pathological evaluation of patient with Parkinson's disease (PD) following intracerebroventricular (icv) GDNF","volume":"24","author":"Palfi S.","year":"1998","journal-title":"Soc. Neurosci. Abstr."},{"key":"e_1_2_6_43_1","volume-title":"The Rat Brain in Stereotaxic Coordinates.","author":"Paxinos G.","year":"1986"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(95)00066-R"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440726"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1999.00566.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00269-8"},{"key":"e_1_2_6_48_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6\u2010hydroxydopamine: a combined retrograde tracing and immunocytochemical study in rat","volume":"59","author":"Sauer H.","year":"1994","journal-title":"Neuroscience"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.19.8935"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.434"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/371336a0"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430309"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199601310-00060"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0497-421"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/358584a0"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/373335a0"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199806010-00027"},{"key":"e_1_2_6_58_1","first-page":"70","article-title":"Growth factor function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF\u2010\u03b2","volume":"196","author":"Unsicker K.","year":"1996","journal-title":"Ciba Found. Symp."},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420115"},{"key":"e_1_2_6_60_1","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1523\/JNEUROSCI.16-22-07206.1996","article-title":"Short\u2010term GDNF treatment provides long\u2010term rescue of lesioned nigral DA neurons in a rat model of Parkinson's disease","volume":"16","author":"Winkler C.","year":"1996","journal-title":"J. Neurosci"}],"container-title":["European Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0953-816x.2001.01473.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0953-816x.2001.01473.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:04:27Z","timestamp":1696291467000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.0953-816x.2001.01473.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1046\/j.0953-816x.2001.01473.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0953-816x.2001.01473.x","archive":["Portico"],"relation":{},"ISSN":["0953-816X","1460-9568"],"issn-type":[{"value":"0953-816X","type":"print"},{"value":"1460-9568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}